Universal Beteiligungs und Servicegesellschaft mbH Buys 147,586 Shares of Arcutis Biotherapeutics, Inc. $ARQT

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH raised its stake in Arcutis Biotherapeutics by 170.6% in Q4, buying 147,586 shares to hold 234,071 shares (about 0.19% of the company) valued at $6.797 million.
• Insiders have been net sellers recently — Masaru Matsuda sold 40,638 shares and Todd Watanabe sold 37,349 shares, with insiders offloading 159,546 shares worth $4.03 million in the past 90 days and now owning 9.40% of the stock.
• Arcutis topped Q4 estimates ( EPS $0.13 vs. $0.03 expected) and revenue of $129.5M, the stock has a market cap of $2.93B and a 12‑month range of $12.42–$31.77, and analysts' consensus is a "Moderate Buy" with an average target of $34.00.

Universal Beteiligungs und Servicegesellschaft mbH lifted its position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 170.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 234,071 shares of the company's stock after purchasing an additional 147,586 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned 0.19% of Arcutis Biotherapeutics worth $6,797,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the company. Merit Financial Group LLC boosted its stake in Arcutis Biotherapeutics by 29.3% in the 4th quarter. Merit Financial Group LLC now owns 13,017 shares of the company's stock valued at $378,000 after purchasing an additional 2,952 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in Arcutis Biotherapeutics by 28.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,952 shares of the company's stock valued at $173,000 after purchasing an additional 1,316 shares during the period. CWM LLC boosted its stake in Arcutis Biotherapeutics by 24.0% in the 4th quarter. CWM LLC now owns 22,459 shares of the company's stock valued at $652,000 after purchasing an additional 4,342 shares during the period. Whalen Wealth Management Inc. bought a new stake in Arcutis Biotherapeutics in the 4th quarter valued at $233,000. Finally, Ellsworth Advisors LLC bought a new stake in Arcutis Biotherapeutics in the 4th quarter valued at $868,000.

Arcutis Biotherapeutics Price Performance

Shares of NASDAQ:ARQT opened at $23.42 on Tuesday. The firm has a 50 day moving average of $24.11 and a 200-day moving average of $25.69. The stock has a market capitalization of $2.93 billion, a PE ratio of -167.27 and a beta of 1.76. The company has a current ratio of 3.17, a quick ratio of 2.99 and a debt-to-equity ratio of 0.57. Arcutis Biotherapeutics, Inc. has a 12 month low of $12.42 and a 12 month high of $31.77.

Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) last issued its earnings results on Wednesday, February 25th. The company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.03 by $0.10. The company had revenue of $129.50 million during the quarter, compared to analysts' expectations of $110.79 million. Arcutis Biotherapeutics had a negative net margin of 4.29% and a negative return on equity of 10.26%. On average, equities research analysts predict that Arcutis Biotherapeutics, Inc. will post 0.32 EPS for the current fiscal year.

Insider Transactions at Arcutis Biotherapeutics

In other Arcutis Biotherapeutics news, insider Masaru Matsuda sold 40,638 shares of the company's stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $25.28, for a total value of $1,027,328.64. Following the completion of the transaction, the insider directly owned 110,003 shares in the company, valued at approximately $2,780,875.84. This represents a 26.98% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Todd Watanabe sold 37,349 shares of the company's stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $25.18, for a total transaction of $940,447.82. Following the completion of the transaction, the insider owned 785,957 shares of the company's stock, valued at approximately $19,790,397.26. This trade represents a 4.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 159,546 shares of company stock worth $4,032,162. 9.40% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of analysts have issued reports on the stock. Zacks Research downgraded shares of Arcutis Biotherapeutics from a "strong-buy" rating to a "hold" rating in a report on Monday, December 29th. TD Cowen boosted their price objective on shares of Arcutis Biotherapeutics from $30.00 to $35.00 and gave the company a "buy" rating in a report on Thursday, February 26th. Wall Street Zen downgraded shares of Arcutis Biotherapeutics from a "strong-buy" rating to a "buy" rating in a report on Saturday, February 14th. Mizuho cut their price objective on shares of Arcutis Biotherapeutics from $37.00 to $35.00 and set an "outperform" rating for the company in a report on Monday, March 2nd. Finally, Needham & Company LLC boosted their price objective on shares of Arcutis Biotherapeutics from $31.00 to $36.00 and gave the company a "buy" rating in a report on Thursday, February 26th. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $34.00.

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company's research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.